Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 11/07/2025 BST			5-day change	1st Jan Change
438.95 ^DKK	-3.64%		-2.74%	-29.68%

07-11	European stocks down with bank and healthcare drag, US-EU tariffs in focus	RE
07-11	FDA May Fast Track Drug Reviews for Lower US Prices	MT

Novo Nordisk regains crown as Europe's most valuable company

Published on 13/06/2025 at 10:09

LONDON (Reuters) -Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP on Friday.

The Danish company reached $367.91 billion in market value, including its unlisted shares, according to LSEG data.

Chipmaker ASML is in third place.

(Reporting by Alun John and Samuel Indyk; Editing by Amanda Cooper)

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ASML HOLDING N.V.	683.90EUR	-0.88%	+3.72%	311B
NOVO NORDISK A/S	438.95DKK	-3.64%	-2.74%	305B
SAP SE	258.75EUR	-1.65%	+1.27%	353B

Latest news about Novo Nordisk A/S

European stocks down with bank and healthcare drag, US-EU tariffs in focus	07-11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	07-11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
NOVO NORDISK : Gets a Buy rating from UBS	07-11	ZD
Wall Street Waits to Hear the Numbers	07-11
Mining, healthcare prop up European shares; US-EU trade talks in focus	07-10	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
European shares close at four-week high on banks boost; US trade talks in focus	07-09	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	07-09	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	07-09	ZD
Europe rises despite new US tariff mayhem	07-09	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
European shares rise on energy, healthcare boost; tariff uncertainty lingers	07-08	RE
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	07-08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	07-08	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	07-08	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	07-08	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	07-08	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	07-08	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	07-08	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	07-08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	07-08	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07-07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07-07	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Release

More about the company